CAS: 259793-96-9; 6-Fluoro-3-Oxo-3,4-Dihydropyrazine-2-Carboxamide

相似化合物

1237524-82-1 259794-01-9 88394-05-2

上下游产品

CAS号356783-31-8 6-氟-3-氧代-3,4-二氢... | CAS号55321-99-8 3-羟基吡嗪-2-酰胺 | CAS号356783-27-2 methyl 6-fluoro... | CAS号356783-42-1 Pyrazinecarboxa... | CAS号356783-16-9 3,6-二氯吡嗪-2-甲腈 | CAS号356783-28-3 3,6-二氟-2-氰基吡嗪

吡嗪酰胺置于硫酸,四丁基氟化铵,四丁基溴化铵,水,Sodium Acetate,溶剂黄146,间氯过氧苯甲酸,三氯氧磷体系中,用 1,4-二氧六环,乙酸乙酯,氯苯 用作溶剂,化学反应 47.83H,反应生成法匹拉韦
参考文献:法匹拉韦的合成工艺
标题:法匹拉韦的合成工艺
摘要:本发明涉及法匹拉韦的合成工艺,包括有以下步骤:1)将吡嗪化合物溶于有机试剂i中,加入氧化剂m,进行氮氧化反应,得白色固体物质;2)将所得白色固体物质加入到有机试剂ii中进行氯化反应,得淡黄色固体;3)将所得淡黄色固体与干燥的非质子极性溶剂,干燥的氟离子供体试剂,四丁基溴化铵混合均匀,搅拌反应,得淡黄色固体;4)将所得淡黄色固体加入到水中,1,4‑二氧六环和乙酸钠,反应得黄色油状物;5)将所得黄色油状物与浓硫酸混匀,可得目标产物法匹拉韦.本发明的方法涉及的原料简单易得,合成工艺简单,条件温和,经氮氧化,氯化,氟代,水解最终制得6‑氟‑3‑羟基吡嗪‑2‑甲酰胺,具有很好的工业化价值.

专利信息

专利号:US-8309099-B2
优先权日:2000-04-28
标 题:DNA transfection system for the generation of negative strand RNA virus
发明人：HOFFMANN ERICH
权利人:HOFFMANN ERICH; ST JUDE CHILDRENS RES HOSPITAL
摘要:The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

专利号:WO-2022009036-A1
优先权日:2020-07-06
标题:Synthesis of favipiravir
发明人：DESI REDDY SRINIVAS REDDY; VEDURURI MADHAVA REDDY
权利人:OPTIMUS DRUGS P LTD
摘要:The present invention relates to 6-Fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt and to an improved and commercially viable process for preparation of Favipiravir using 6-fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt.

专利号:WO-2024028893-A1
优先权日:2022-08-01
标 题:Substituted benzimidazoles for treating viral diseases
发明人：CHAUDHARI VINOD DINKAR; THAKUR KRISHAN GOPAL; RINGE RAJESH PRAKASH; SINGH DESHKANWAR; KAUR SIMRAN; CHAWLA RAVNEET SINGH; JOSHI AKSHAY
权利人:COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN OF S
摘要:The invention relates to benzimidazole compounds, pharmaceutically acceptable salts thereof and its pharmaceutical compositions for reducing/treating viral infections. The present invention also relates to synthesis of such benzimidazole compounds. The present invention further relates to compositions which comprise such benzimidazole compounds or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination. The compounds of the invention are useful in reducing/treating viral infections particularly coronavirus infections caused by SARS-CoV, MERS-CoV and SARS-CoV-2.

专利号:US-2023364251-A1
优先权日:2020-08-06
标 题:Methods for the synthesis of protein-drug conjugates
发明人：BORCHARDT ALLEN; HUGHES ROBERT MICHAEL
权利人:CIDARA THERAPEUTICS INC
摘要:The present invention relates to intermediates and methods for synthesizing protein-drug conjugates that can be used for the treatment of diseases and related conditions.

专利号:US-9181203-B2
优先权日:2010-11-12
标题:Substituted pyrazino[2,3-d]isooxazoles as intermediates for the synthesis of substituted pyrazinecarbonitriles and substituted pyrazinecarboxamides
发明人：NAKAMURA KOUKI; MURAKAMI TAKESHI; NAITOU HIROYUKI; HANAKI NAOYUKI; WATANABE KATSUYUKI
权利人:FUJIFILM CORP; TOYAMA CHEMICAL CO LTD
摘要:The object of the present invention is to provide a compound which is useful as a production intermediate of pyrazine carboxamide derivative such as 6-fluoro-3-hydroxy-2-pyrazine carboxamide. The present invention provides a pyrazino[2,3-d]isoxazole derivative represented by the formula (I): n nwherein X represents a halogen atom, a hydroxyl group or a sulfamoyloxy group, and Y represents —C(â•?O)R or —CN; wherein R represents a hydrogen atom, an alkoxy group an aryloxy group, an alkyl group, an aryl group or an amino group.

专利号:US-2024207302-A1
优先权日:2021-04-01
标 题 :Antiviral compounds, methods for the manufacturing of compounds, antiviral pharmaceutical composition, use of the compounds and method for the oral treatment of coronavirus infection and related diseases thereof
发明人：CALIXTO JOãO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO
权利人:CALIXTO JOAO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO
摘要:The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-COV-2 and MHIV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-COV-2 and of patients with COVID-19, individual infected with SARS-COV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-COV-2 was greatly enhanced by inhibiting the 3′-5′-exonuclease. Synergistic results of the compounds according to the present invention were obtained from the combination with repurposed drugs.